Autotaxin and vascular endothelial growth factor receptor‐2 and ‐3 are related to vascular development during the progression of chronic viral hepatitis C

Apmis ◽  
2018 ◽  
Vol 126 (12) ◽  
pp. 913-921
Author(s):  
Hiroaki Yokomori ◽  
Wataru Ando ◽  
Fumihiko Kaneko ◽  
Hidekazu Suzuki ◽  
Koji Igarashi ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Hepatitis C ◽  
Growth Factor ◽  
Viral Hepatitis ◽  
Growth Factor Receptor ◽  
Chronic Viral Hepatitis ◽  
Vascular Endothelial ◽  
Viral Hepatitis C ◽  
Endothelial Growth Factor ◽  
Chronic Viral Hepatitis C

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document